Overview

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Status:
Completed

Trial end date:
2007-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the analgesic effectiveness and safety of 37.5mg Tramadol hydrochloride/325mg Acetaminophen in the treatment of breakthrough pain in cancer patients.

Phase:

Phase 4

Details

Lead Sponsor:

Johnson & Johnson Taiwan Ltd

Treatments:

Acetaminophen
Tramadol